Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunological Targeting of CD-133 in Recurrent Glioblastoma: A Multi-center Phase I Translational and Clinical Study of an Autologous CD-133 DC Vaccine

NCT02049489 is registered in ClinicalTrials.gov with Precision Life Sciences Group as lead sponsor.

NCT NCT02049489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02049489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunological Targeting of CD-133 in Recurrent Glioblastoma: A Multi-center Phase I Translational and Clinical Study of an Autologous CD-133 DC Vaccine
Lead sponsor
Precision Life Sciences Group
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2013
Completion date
March 31, 2017
Enrollment
20 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme